Discrimination and reclassification for 5-y all-cause mortality in the FINRISK cohort with and without circulating biomarkers in the risk prediction score.

Risk discrimination was assessed for FINRISK study participants with the risk prediction scores derived in the Estonian Biobank cohort (Table 2). The reference risk score included age, sex, body mass index, systolic blood pressure, fasting time, total cholesterol, HDL cholesterol, triglycerides, creatinine, smoking status, alcohol consumption, prevalent diabetes, prevalent cardiovascular disease, and prevalent cancer. The biomarker risk prediction score was extended with alpha-1-acid glycoprotein, albumin, VLDL particle size, and citrate. Complete data were available for 7,110 individuals, of which 157 died during the 5-y follow-up period. Category-based reclassification was assessed for four risk categories (≤1.25%, 1.25%–2.5%, 2.5%–5%, ≥5%) based on the reference risk score and the biomarker risk score. Reclassification tables for these groups and model calibration of the prediction scores within risk deciles are shown in Figure S3 and Table S2.

本研究针对芬兰风险研究（FINRISK）的受试者，基于爱沙尼亚生物样本库（Estonian Biobank）队列构建的风险预测评分，对其风险区分度进行了评估（见表2）。参考风险评分纳入了年龄、性别、体质量指数、收缩压、空腹时长、总胆固醇、高密度脂蛋白（HDL）胆固醇、甘油三酯、肌酐、吸烟状态、饮酒量、既往糖尿病、既往心血管疾病及既往癌症史。生物标志物风险预测评分则额外纳入了α-1-酸性糖蛋白、白蛋白、极低密度脂蛋白（VLDL）颗粒大小及枸橼酸盐。共有7110名受试者拥有完整数据，其中157名在5年随访期间死亡。基于参考风险评分与生物标志物风险评分，对四类风险分层（≤1.25%、1.25%~2.5%、2.5%~5%及≥5%）进行了基于类别的重分类评估。上述分组的重分类表以及风险十分位内预测评分的模型校准结果，详见补充图S3与补充表S2。